Serum levels of 1-84 and 7-84 parathyroid hormone in predialysis patients with chronic renal failure measured by the intact and bio-PTH assay

Nephron - Clinical Practice

Volumn 102, Issue 3-4, 2006, Pages

  Tsuchida, Takao ^a   Ishimura, Eiji ^a   Hirowatari, Kaname ^a   Matsumoto, Naoki ^a   Imanishi, Yasuo ^a   Jono, Shuichi ^a   Miki, Takami ^a   Inaba, Masaaki ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic renal failure, predialysis; Fragment, PTH(7 84) like; Parathyroid hormone, intact

Indexed keywords

BIOLOGICAL MARKER; CREATININE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-84]; PARATHYROID HORMONE[7-84]; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METABOLISM; CALCULATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDE FRAGMENTS;

EID: 33344476518     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089668     Document Type: Article

References (34)

1. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-2105.
2. Parfitt AM: A structural approach to renal bone disease. J Bone Miner Res 1998;13: 1213-1220.
3. Ho LT, Sprague SM: Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002;22: 488-493.
4. Slatopolsky E, Gonzalez E, Martin K: Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003;21:318-326.
5. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844.
6. Medical-Expert-Group: Clinical algorithms on renal osteodystrophy. Nephrol Dial Transplant 2000;15(suppl 5):39-57.
7. Massry S, Coburn J: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):S1-S201.
8. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y: Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002;40:802-809.
9. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-809.
10. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-761.
11. Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M: Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. Clin Exp Nephrol 2003;7:144-149.
12. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:1460-1468.
13. Divieti P, John MR, Juppner H, Bringhurst FR: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002;143:171-176.
14. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001;142:1386-1392.
15. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84: 4287-4290.
16. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16: 605-614.
17. Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y: Technical and clinical characterization of the bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004;50:385-390.
18. Tanno Y, Yokoyama K, Nakayama M, Katoh A, Yamamoto H, Iwasaki Y, Cantor T, Fukagawa M, Shigematsu T, Hosoya T: IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. Nephrol Dial Transplant 2003;18(suppl 3):iii97-iii98.
19. Hatakeyama Y, Mizunashi K, Furukawa Y, Yabuki S, Sato Y, Igarashi T: Plasma levels of parathyroid hormone (1-84) whole molecule and parathyroid hormone (7-84)-like fragments in pseudohypoparathyroidism type I. J Clin Endocrinol Metab 2003;88:2250-2255.
20. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55:1019-1027.
21. Fraser WD, Durham BH, Berry JL, Mawer EB: Measurement of plasma 1.25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem 1997;34: 632-637.
22. Gault MH, Longerich LL, Harnett JD, Wesolowski C: Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249-256.
23. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A, Komori T: Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001;155:157-166.
24. Tsuchida T, Ishimura E, Miki T, Matsumoto N, Naka H, Jono S, Inaba M, Nishizawa Y: The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 2005;16:172-179.
25. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT: Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-1566.
26. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85:4157-4161.
27. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A, Morii H: Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 1999;9:525-531.
28. Takahashi M, Kushida K, Nagano A, Inoue T: Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 2000;294:67-76.
29. Tahtela R, Turpeinen M, Sorva R, Karonen SL: The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin Biochem 1997;30:35-40.
30. Furumitsu Y, Inaba M, Yukioka K, Yukioka M, Kumeda Y, Azuma Y, Ohta T, Ochi T, Nishizawa Y, Morii H: Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 2000;27:64-70.
31. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K, Tsuzuki T: Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 1995;235:33-40.
32. Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN: Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998;23:471-477.
33. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D: PTH 1-84 and PTH '7-84' in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002;40:348-354.
34. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003;63:1801-1808.